Login to Your Account

Uniqure, Chiesi Ink $40M Deal in Europe, China for Glybera

By Cormac Sheridan
Staff Writer

Wednesday, July 10, 2013
Gene therapy pioneer Uniqure BV is banking €31 million (US$39.6 million) through a commercialization and equity deal with Chiesi Famaceutici SpA that involves European and Chinese rights to its approved gene therapy product, Glybera (alipogene tiparvovec), as well as rights in Europe and several other territories to its hemophilia B gene therapy program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription